ATE334686T1 - Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie - Google Patents
Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapieInfo
- Publication number
- ATE334686T1 ATE334686T1 AT00916269T AT00916269T ATE334686T1 AT E334686 T1 ATE334686 T1 AT E334686T1 AT 00916269 T AT00916269 T AT 00916269T AT 00916269 T AT00916269 T AT 00916269T AT E334686 T1 ATE334686 T1 AT E334686T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor therapy
- improvement
- sphingomyelin
- composition containing
- containing sphingomyelin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 abstract 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 229940106189 ceramide Drugs 0.000 abstract 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12618999P | 1999-03-25 | 1999-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334686T1 true ATE334686T1 (de) | 2006-08-15 |
Family
ID=22423475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00916269T ATE334686T1 (de) | 1999-03-25 | 2000-03-24 | Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie |
| AT06075201T ATE512664T1 (de) | 1999-03-25 | 2000-03-24 | Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06075201T ATE512664T1 (de) | 1999-03-25 | 2000-03-24 | Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6541462B1 (de) |
| EP (2) | EP1666045B1 (de) |
| JP (1) | JP2002540172A (de) |
| AT (2) | ATE334686T1 (de) |
| AU (1) | AU3740000A (de) |
| CA (2) | CA2707691C (de) |
| DE (1) | DE60029762T2 (de) |
| ES (1) | ES2269121T3 (de) |
| WO (1) | WO2000057916A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7683044B2 (en) * | 1999-03-25 | 2010-03-23 | Center For Molecular Medicine And Immunology | Sphingomyelin therapy of autoimmune disease |
| ATE334686T1 (de) * | 1999-03-25 | 2006-08-15 | Ct Molecular Med & Immunology | Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie |
| WO2007034927A1 (ja) | 2005-09-22 | 2007-03-29 | Snow Brand Milk Products Co., Ltd. | スフィンゴミエリン含有医薬、飲食品または飼料 |
| WO2008147481A1 (en) * | 2007-02-09 | 2008-12-04 | Northeastern University | Precision-guided nanoparticle systems for drug delivery |
| ES2824074T3 (es) | 2013-01-24 | 2021-05-11 | Memorial Sloan Kettering Cancer Center | Método para diagnosticar o tratar tumores mediante el uso de liposomas que contienen esfingomielina |
| US9851358B2 (en) * | 2014-01-08 | 2017-12-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination |
| GB201414464D0 (en) * | 2014-08-14 | 2014-10-01 | Technion Res & Dev Foundation | Compositions and methods for therapeutics prescreening |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5859912A (ja) * | 1981-10-06 | 1983-04-09 | Green Cross Corp:The | 鎮痛消炎物質脂肪乳剤 |
| EP1008342A3 (de) * | 1994-02-02 | 2004-12-29 | The Liposome Company, Inc. | Pharmazeutisch aktive Verbindungen und Liposome, und deren Verwendung |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5800833A (en) * | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| ATE279185T1 (de) * | 1995-12-28 | 2004-10-15 | Mitsubishi Pharma Corp | 2-amino-2-(2-(4-octylphenyl)ethyl)propan-1,3-di l enthaltendes arzneimittel zur topischen anwendung zur behandlung von erkrankungen die durch eine störung des immunsystems hervorgerufen werden |
| WO1998045463A1 (en) * | 1997-04-07 | 1998-10-15 | Daiichi Pharmaceutical Co., Ltd. | Composition for gene introduction into cell |
| ATE334686T1 (de) * | 1999-03-25 | 2006-08-15 | Ct Molecular Med & Immunology | Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie |
-
2000
- 2000-03-24 AT AT00916269T patent/ATE334686T1/de not_active IP Right Cessation
- 2000-03-24 DE DE60029762T patent/DE60029762T2/de not_active Expired - Lifetime
- 2000-03-24 CA CA2707691A patent/CA2707691C/en not_active Expired - Fee Related
- 2000-03-24 CA CA2368676A patent/CA2368676C/en not_active Expired - Fee Related
- 2000-03-24 AT AT06075201T patent/ATE512664T1/de not_active IP Right Cessation
- 2000-03-24 WO PCT/US2000/006431 patent/WO2000057916A1/en not_active Ceased
- 2000-03-24 JP JP2000607665A patent/JP2002540172A/ja active Pending
- 2000-03-24 US US09/533,799 patent/US6541462B1/en not_active Expired - Lifetime
- 2000-03-24 ES ES00916269T patent/ES2269121T3/es not_active Expired - Lifetime
- 2000-03-24 EP EP06075201A patent/EP1666045B1/de not_active Expired - Lifetime
- 2000-03-24 AU AU37400/00A patent/AU3740000A/en not_active Abandoned
- 2000-03-24 EP EP00916269A patent/EP1165137B1/de not_active Expired - Lifetime
-
2003
- 2003-02-14 US US10/366,704 patent/US7288534B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7288534B2 (en) | 2007-10-30 |
| EP1666045B1 (de) | 2011-06-15 |
| AU3740000A (en) | 2000-10-16 |
| DE60029762T2 (de) | 2007-10-18 |
| ATE512664T1 (de) | 2011-07-15 |
| EP1165137B1 (de) | 2006-08-02 |
| CA2368676C (en) | 2010-09-07 |
| CA2707691A1 (en) | 2000-10-05 |
| WO2000057916A1 (en) | 2000-10-05 |
| US6541462B1 (en) | 2003-04-01 |
| CA2368676A1 (en) | 2000-10-05 |
| ES2269121T3 (es) | 2007-04-01 |
| DE60029762D1 (de) | 2006-09-14 |
| CA2707691C (en) | 2013-09-03 |
| JP2002540172A (ja) | 2002-11-26 |
| US20030228257A1 (en) | 2003-12-11 |
| EP1666045A1 (de) | 2006-06-07 |
| EP1165137A1 (de) | 2002-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ID26956A (id) | Pencegahan raf kinase menggunakan simetris dan nonsimetris yang digantikan diphenil urea | |
| ATE312103T1 (de) | Substituierte porphyrine und deren therapeutische verwendungen | |
| DK0612248T3 (da) | Præparat, der indeholder cisplatin og topotecan som antitumormiddel | |
| ATE399560T1 (de) | Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von nicht-hodgkihn- lymphome | |
| MXPA04003674A (es) | Uso mejorado de compuesto antitumoral en terapia de cancer. | |
| MX9101913A (es) | Derivados de quinazolinas para potenciar la actividad antitumoral | |
| DE60324427D1 (de) | Verfahren zur modulation der tubulindeacetylase-aktivität | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| DK1137762T3 (da) | Behandling af Pompes sygdom | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| GB9415167D0 (en) | Improvements relating to cancer therapy | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| WO2000018439A3 (de) | Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren | |
| DK0944389T3 (da) | Oprensede sammensætninger af 10-propargyl-10-deazaaminopterin og fremgangsmåder til anvendelse deraf i behandlingen af tumorer | |
| ATE406897T1 (de) | Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs | |
| SE0102147D0 (sv) | New methods | |
| DE60029762D1 (de) | Sphingomyelin enthaltende zusammensetzung zur verbesserung der tumortherapie | |
| WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
| DE69835461D1 (de) | Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren | |
| DE60222383D1 (de) | Medikament zur verabreichung von amifostin und verwandten wirkstoffen | |
| TR199901782T2 (xx) | Migren tedavisi i�in ibuprofen ve domperidon ihtiva eden farmas�tik bile�imler. | |
| AU4789099A (en) | Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents | |
| JO2199B1 (en) | Replaced pyrrols | |
| NZ536111A (en) | Statin therapy for enhancing cognitive maintenance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |